RMD
ResMed Inc
222.00$
-0.7%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.5% | +12.4% | +13.2% | +11.4% | +13.4% | +8.1% | +11.9% | +18.0% | +10.9% | +9.8% | +9.9% | |
| – | +15.7% | +12.0% | +13.1% | +9.4% | +15.8% | +9.6% | +14.4% | +20.2% | +8.7% | +3.0% | +5.0% | |
| – | +5.4% | +12.7% | +13.3% | +12.8% | +11.8% | +7.1% | +10.1% | +16.4% | +12.7% | +15.1% | +13.2% | |
| – | +3.3% | +21.8% | +7.4% | +16.4% | +11.8% | +11.6% | +12.6% | +13.4% | +6.9% | +7.7% | +14.2% | |
| – | +2.0% | +13.5% | +8.4% | +7.4% | +4.9% | -0.9% | +10.3% | +18.2% | +4.9% | +8.1% | +13.0% | |
| – | +3.8% | +24.1% | +5.7% | +16.7% | -5.1% | +2.9% | +9.5% | +19.5% | +9.1% | +2.6% | +14.3% | |
| – | +4.8% | -0.7% | +27.3% | +6.9% | +39.8% | +11.6% | +10.7% | +13.2% | +16.6% | +27.7% | +12.3% | |
| – | +93.9% | +152.0% | +0.4% | +27.5% | +11.7% | -40.6% | -7.0% | +112.3% | -3.5% | -72.4% | +130.2% | |
| – | +0.8% | -4.7% | +24.5% | -0.5% | +41.3% | +20.5% | +8.7% | +14.7% | +14.8% | +32.6% | +14.4% | |
| – | +5.0% | -12.3% | +169.1% | -44.5% | -2.5% | +267.2% | -55.8% | +12.7% | +19.5% | +13.5% | +43.1% | |
| – | -0.1% | -2.9% | -7.8% | +28.2% | +53.7% | -23.7% | +64.3% | +15.2% | +13.7% | +37.2% | +8.8% | |
| – | +12.1% | +5.2% | +19.6% | +3.8% | +40.3% | +11.5% | +6.6% | +15.5% | +12.9% | +24.8% | +12.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.